Dong Shan Lin

US Patent:

7219228, May 15, 2007

Filed:

Sep 29, 2003

Appl. No.:

10/674208

Inventors:

Dong Lin - Fort Lee NJ, US

Assignee:

Lucent Technologies Inc. - Murray Hill NJ

International Classification:

G06F 9/00

US Classification:

713160, 713161, 713165, 713166

Abstract:

A SYN packet bandwidth Distributed Denial-of-Service (DDoS) attack is defended against by intercepting and identifying SYN packets in a “DDoS gateway” advantageously positioned at the edge of the network to be protected (e. g. , one hop upstream from the protected link), and by queuing these intercepted SYN packets in a separate queue from other TCP packet queues. Edge per-flow queuing is employed to provide isolation among individual TCP connections sharing the link. A fair scheduling algorithm such as round robin scheduling is used to ensure that SYN packets (such as those generated as part of a SYN bandwidth attack) cannot overwhelm the egress link in the presence of other TCP packets.

US Patent:

7404210, Jul 22, 2008

Filed:

Sep 23, 2003

Appl. No.:

10/668952

Inventors:

Dong Lin - Fort Lee NJ, US

Assignee:

Lucent Technologies Inc. - Murray Hill NJ

International Classification:

G06F 11/00

US Classification:

726 22, 370392, 713188

Abstract:

A Distributed Denial-of-Service (DDoS) attack by a TCP stateless hog is defeated with use of an enhancement to the keep-alive mechanism provided by RFC 1122. A TCP server receives a new TCP connection request from a possible attacker and sends a keep-alive probe packet back thereto using an “invalid” sequence number. Illustratively, this “invalid” sequence number comprises a random number selected to be reasonably distant from the actual current sequence number. When a responsive packet is received from the potential attacker, the TCP server verifies the accuracy of the acknowledgement number in the received packet, thereby determining whether the potential attacker may be a TCP stateless hog.

US Patent:

20220259222, Aug 18, 2022

Filed:

Jan 28, 2022

Appl. No.:

17/587555

Inventors:

- Summit NJ, US
John R. Coombs - New Brunswick NJ, US
Keming Zhu - New Brunswick NJ, US
Daniel Lim - Summit NJ, US
Candice Lee Joe - New Brunswick NJ, US
David T. George - New Brunswick NJ, US
Bin Zheng - Kendall Park NJ, US
Dong Lin - Monmouth Junction NJ, US

International Classification:

C07D 495/14
C07C 255/50
C07D 215/58
C07D 495/04

Abstract:

The present disclosure provides novel synthetic intermediates useful in the synthesis of MK2 kinase inhibitors.

US Patent:

20210107897, Apr 15, 2021

Filed:

Dec 22, 2020

Appl. No.:

17/131718

Inventors:

- Princeton NJ, US
Joerg Deerberg - Columbus NJ, US
Dong Lin - Monmouth Junction NJ, US
Michael Dummeldinger - Plainsboro NJ, US
Bahar Inankur - New Brunswick NJ, US
Sergei Kolotuchin - Roselle Park NJ, US
Jun Li - Langhorne PA, US
Amanda J. Rogers - Asbury NJ, US
Victor W. Rosso - Monroe Township NJ, US
Eric M. Simmons - East Brunswick NJ, US
Maxime C.D. Soumeillant - Princeton NJ, US
Daniel S. Treitler - Cranford NJ, US
Jianji Wang - Dayton NJ, US
Bin Zheng - Kendall Park NJ, US
Michael J. Smith - Somerset NJ, US
Neil A. Strotman - Flemington NJ, US
Steven Tymonko - Lindenhurst IL, US
Tamas Benkovics - East Brunswick NJ, US

International Classification:

C07D 403/12
C07C 211/09
C07D 237/24
C07D 249/08

Abstract:

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula:Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

US Patent:

20200109134, Apr 9, 2020

Filed:

Mar 29, 2018

Appl. No.:

16/498442

Inventors:

- Princeton NJ, US
Joerg Deerberg - Columbus NJ, US
Dong Lin - Monmouth Junction NJ, US
Michael Dummeldinger - Plainsboro NJ, US
Bahar Inankur - New Brunswick NJ, US
Sergei Kolotuchin - Roselle Park NJ, US
Jun Li - Langhorne PA, US
Amanda J. Rogers - Asbury NJ, US
Victor W. Rosso - Monroe Township NJ, US
Eric M. Simmons - East Brunswick NJ, US
Maxime C.D. Soumeillant - Princeton NJ, US
Daniel S. Treitler - Cranford NJ, US
Jianji Wang - Dayton NJ, US
Bin Zheng - Kendall Park NJ, US
Michael J. Smith - Somerset NJ, US
Neil A. Strotman - Flemington NJ, US
Steven Tymonko - Lindenhurst IL, US
Tamas Benkovics - East Brunswick NJ, US

International Classification:

C07D 403/12
C07D 249/08
C07C 211/09
C07D 237/24

Abstract:

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.